32,135 Shares in Becton, Dickinson and Company $BDX Purchased by Core Capital Management & Research inc.

Posted by George Bondi on Sep 10th, 2026

Core Capital Management & Research inc. purchased a new stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 32,135 shares of the medical instruments supplier’s stock, valued at approximately $4,863,000. Becton, Dickinson and Company makes up 2.6% of Core Capital Management & Research inc.’s holdings, making the stock its 12th largest holding.

Several other hedge funds also recently modified their holdings of BDX. Brighton Jones LLC grew its holdings in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the last quarter. Northside Capital Management LLC lifted its position in shares of Becton, Dickinson and Company by 18.3% during the second quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock worth $9,280,000 after purchasing an additional 9,494 shares in the last quarter. Cooke & Bieler LP lifted its position in shares of Becton, Dickinson and Company by 27.2% during the fourth quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock worth $218,614,000 after purchasing an additional 240,673 shares in the last quarter. Beverly Hills Private Wealth LLC bought a new stake in shares of Becton, Dickinson and Company during the second quarter valued at approximately $3,353,000. Finally, Wealthfront Advisers LLC acquired a new stake in shares of Becton, Dickinson and Company in the second quarter valued at approximately $2,567,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling

In related news, EVP Michael Garrison sold 1,100 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. The trade was a 3.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 8,005 shares of company stock valued at $1,423,580. Insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

BDX has been the subject of several research reports. TD Cowen lifted their target price on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Bank of America raised their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Monday, August 31st. Weiss Ratings reiterated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Finally, Piper Sandler upped their target price on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $187.67.

Read Our Latest Report on BDX

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $179.92 on Thursday. The firm has a fifty day moving average of $171.75 and a two-hundred day moving average of $160.59. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock has a market capitalization of $49.57 billion, a price-to-earnings ratio of 54.19, a PEG ratio of 12.62 and a beta of 0.21. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $193.07.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD’s products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.